List of Marijuana/Cannabinoid-Derived Drugs Companies in Israel - 8

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) is a public biotech company that has developed a patented Botanical Synthesis platform technology capable of growing the active and beneficial compounds in fruit & plants, at an industrial scale, without the need to grow the plant itself. BioHarvest has invested 16 years and >$75M to develop our Botanical Synthesis Technology, which produces unique and patentable botanical compositions which contain a "target optimized" combination of the phyto-medicinal compounds (with high solubility and bio-availability) found in the original plant. No other company has developed a commercially viable plant cell culture platform at the industrial scale of BioHarvest. BioHarvest is focused on leveraging this platform technology across the following business units: 1. Plant Cell Culture Development and Manufacturing: BioHarvest is leveraging its Botanical Synthesis technology to allow global pharmaceutical, cosmeceutical, and nutraceutical partners to develop proprietary botanical formulations with unmatched predictability and consistency, manufactured at industrial scale under exclusive partnerships. 2. Direct to Consumer/Direct to Doctor Nutraceuticals Business Anchored in Science: BioHarvest has built its own direct to consumer business of propriety botanical compositions. The first product, VINIA® was launched into the US in 2021 and has exceeded 50,000 users (>$20M USD Revenue). VINIA® contains multiple polyphenols, including Piceid Resveratrol, with an amount in each daily 400mg capsule that is equivalent to 1,000 grapes, resulting in a powerful nutraceutical that has been clinically proven (in a published double-blind placebo-controlled study), to significantly increase dilation of arteries. This increased dilation of arteries improves blood flow and the delivery of oxygen and nutrients to the body, tissue & organs. BioHarvest is the only company that produces red grape sourced Piceid resveratrol at an industrial scale

Gynica is a femtech company leading in the clinical development of cannabinoid-based therapeutic solutions to treat gynecological conditions and improve women's quality of life. We aim to provide evidence-based products that use an innovative local approach to effectively address undertreated gynecological conditions, such as painful menstruation and painful sexual intercourse, with no side effects. Why? 1. Women's health is experiencing a tidal wave of innovation, as both patients and physicians are looking for solutions that will specifically address women's health, tailor-made to women's biology. 2. Second only to the brain, the female reproductive system has the highest percentage of Anandamide endocannabinoid receptors, creating a potential special effect on women's health. We have made it our mission to develop new formulations, drug delivery methods, and technologies that will focus on utilizing this connection to provide effective medical products to women. As of today, we are the only company in Israel licensed to research the connection between cannabis and women's health. Gynica is led by world-renowned opinion leaders in gynecology, cannabinoids, and pharmacology. Our Board of Directors is Chaired by Prof. Moshe Hod, a leading expert in the field of women's health and the President of the European Association of Perinatal Medicine (EAPM). Our Scientific Committee is led by award-winner Prof. Lumir Ondrej Hanuš – the one behind the ground-breaking discovery of the endocannabinoid system, paving the way for decades of research into medical cannabis use. Gynica was founded in 2017 and our HQ is in Tel Aviv.

InnoCan Pharma is a pharmaceutical company specializing in developing novel therapeutics that harness the unique healing properties of Cannabinoids to improve quality of life. OUR ADVANTAGES Led by a highly-experienced team with a proven track record of success, InnoCan will leverage Israel’s worldleading medical cannabis research community to develop powerful, Cannabinoid-combined, patent-pending formulas. Our outstanding products will be clinically validated by undertaking Post Marketing Surveillance (PMS) studies and combine smart delivery systems to enhance the potency and efficacy of current products for better results. EXPECTED EARLY REVENUES: InnoCan expects to generate early revenues ($30 million in 5 years) from the multi-billion dollar Over The Counter (OTC) market by leveraging the rapid FDA OTC drug monograph process or similar regulatory pathways in Europe and Canada. These regulatory pathways enable InnoCan, in a very short time, to bring to market outstanding new products that combine the huge therapeutic potential of Cannabinoid complex/hemp oil added “excipients” to existing approved OTC drugs. TECHNOLOGY: POWERFUL, PATENT PENDING FORMULAS WITH SMART DELIVERY SYSTEMS InnoCan's products will be highly differentiated within the market through the powerful synergistic effect of the Cannabis-complex Hemp Oil with the active ingredients, combined with our on-demand release delivery system providing improved patient efficacy and compliance. FIRST-LINE PRODUCTS: A LEAP-FORWARD IN DERMATOLOGY TREATMENT DESIGN The companies first products will initially target the multi-billion dollars markets of psoriasis and localized pain , where research shows topical cannabinoid-combined treatments are highly effective, followed by oral hygiene, eczema/ itching, skin support after chemotherapy and women's health. To join the investment opportunity with InnoCan, please contact Iris Bincovich at IrisB@InnocanPharma.com.

An internationally-recognized and multi-disciplinary applied research institute, MIGAL specializes in biotechnology and computational sciences, plant science, precision agriculture and environmental sciences as well as food, nutrition and health.

Panaxia is a pharmaceutical company specializing in medical cannabis R&D and manufacturing. We are bringing scientific rigor and pharmaceutical manufacturing standards to the rapidly evolving field of medical cannabis. As a leader in this category, Panaxia is spearheading the adoption of cannabis-based treatments by developing consistent, effective, high-quality products that can be taken through a variety of familiar delivery methods to substantially improve the lives of people with a wide range of medical conditions. We offer over 65 different products, all manufactured under extremely stringent Good Manufacturing Practice (GMP) guidelines and with the most advanced analytical and validation methods to meet the most demanding requirements for consistency and dosage accuracy. Panaxia is part of a group of leading Israeli pharmaceutical companies with more than four decades of experience and proven success. We invest substantially in research and development and have clinical partnerships with prominent medical centers. Operating around the globe, our network is extensive and ever growing. Collaborating with the world's best medical cannabis companies and organizations enables us to bring cannabis products of the highest quality and consistency to as many people as possible.

RCK is an Israeli cannabis company, breeding repeatable & stable cannabis hybrid-seeds, for both medical & recreational markets.

SciSparc Ltd. (NASDAQ: SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 (formerly THX-110) for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; SCI-160 (formerly THX-160) for the treatment of pain; and SCI-210 (formerly THX-210) for the treatment of autism spectrum disorder and epilepsy.

STERO, founded in 2017 and headquartered in Israel, is a clinical-stage company committed to the research and development of novel and improved Cannabidiol (CBD) based treatment solutions that will potentially benefit millions of patients by reducing the side effects and the need of steroid therapy. STERO's extremely wide coverage patent (CBD from any source, in any combination, any dosage, in any delivery system, all for more than 130 diseases by name) was Issued in the US on August 2018 and is pending in main countries around the world. Stero currently has 3 ongoing clinical trials, 2 phase 2a clinical trials in Crohn's disease, and in Chronic Urticaria (Hives), 1 phase 1/2 clinical trial treating severe covid-19 patients, all covered by Stero's IP & pursuing the FDA drug route, with more in the pipeline.